|Circulating tumor cells, disease progression, and survival in metastatic breast cancer|
M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, J Matera, MC Miller, ...
New England Journal of Medicine 351 (8), 781-791, 2004
|Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer|
C Liedtke, C Mazouni, KR Hess, F André, A Tordai, JA Mejia, ...
Journal of clinical oncology 26 (8), 1275-1281, 2008
|Breast cancer molecular subtypes respond differently to preoperative chemotherapy|
R Rouzier, CM Perou, WF Symmans, N Ibrahim, M Cristofanilli, ...
Clinical cancer research 11 (16), 5678-5685, 2005
|Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system|
S Riethdorf, H Fritsche, V Müller, T Rau, C Schindlbeck, B Rack, W Janni, ...
Clinical cancer research 13 (3), 920-928, 2007
|Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in …|
AU Buzdar, NK Ibrahim, D Francis, DJ Booser, ES Thomas, RL Theriault, ...
Journal of clinical oncology 23 (16), 3676-3685, 2005
|Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer|
M Cristofanilli, DF Hayes, GT Budd, MJ Ellis, A Stopeck, JM Reuben, ...
Journal of clinical oncology 23 (7), 1420-1430, 2005
|Palbociclib in hormone-receptor–positive advanced breast cancer|
NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, ...
New England Journal of Medicine 373 (3), 209-219, 2015
|Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival|
DF Hayes, M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, MC Miller, ...
Clinical Cancer Research 12 (14), 4218-4224, 2006
|Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous …|
M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ...
The Lancet Oncology 17 (4), 425-439, 2016
|Circulating tumor cells in patients with breast cancer dormancy|
S Meng, D Tripathy, EP Frenkel, S Shete, EZ Naftalis, JF Huth, PD Beitsch, ...
Clinical cancer research 10 (24), 8152-8162, 2004
|Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer|
GT Budd, M Cristofanilli, MJ Ellis, A Stopeck, E Borden, MC Miller, ...
Clinical Cancer Research 12 (21), 6403-6409, 2006
|Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer|
FJ Esteva, V Valero, D Booser, LT Guerra, JL Murray, L Pusztai, ...
Journal of Clinical Oncology 20 (7), 1800-1808, 2002
|Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification|
AD Seidman, MN Fornier, FJ Esteva, L Tan, S Kaptain, A Bach, ...
Journal of Clinical Oncology 19 (10), 2587-2595, 2001
|Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors|
V Guarneri, K Broglio, SW Kau, M Cristofanilli, AU Buzdar, V Valero, ...
Journal of clinical oncology 24 (7), 1037-1044, 2006
|Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks|
MC Green, AU Buzdar, T Smith, NK Ibrahim, V Valero, MF Rosales, ...
Journal of Clinical Oncology 23 (25), 5983-5992, 2005
|Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer|
M Kaufmann, G Von Minckwitz, EP Mamounas, D Cameron, LA Carey, ...
Annals of surgical oncology 19 (5), 1508-1516, 2012
|International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment|
S Dawood, SD Merajver, P Viens, PB Vermeulen, SM Swain, TA Buchholz, ...
Annals of oncology 22 (3), 515-523, 2011
|Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer|
R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ...
Clinical cancer research 20 (7), 1757-1767, 2014
|Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer.|
C Fribbens, B O'Leary, L Kilburn, S Hrebien, I Garcia-Murillas, M Beaney, ...
|Fingerprinting the circulating repertoire of antibodies from cancer patients|
PJ Mintz, J Kim, KA Do, X Wang, RG Zinner, M Cristofanilli, MA Arap, ...
Nature biotechnology 21 (1), 57-63, 2003